Hemophagocytosis, hyper-inflammatory responses, and multiple organ damages in COVID-19-associated hyperferritinemia
AbstractHyperferritinemia comes to light frequently in general practice. However, the characteristics of COVID-19-associated hyperferritinemia and the relationship with the prognosis were not well described. The retrospective study included 268 documented COVID-19 patients. They were divided into the hyperferritinemia group ( ≥ 500 µg/L) and the non-hyperferritinemia group (
Source: Annals of Hematology - December 4, 2021 Category: Hematology Source Type: research

Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement
AbstractPlatelet-derived growth factor receptor B (PDGFRB) gene rearrangements define a unique subgroup of myeloid and lymphoid neoplasms frequently associated with eosinophilia and characterized by high sensitivity to tyrosine kinase inhibition. To date, variousPDGFRB/5q32 rearrangements, involving at least 40 fusion partners, have been reported. However, information on genomic and clinical features accompanying rearrangements ofPDGFRB is still scarce. Here, we characterized a series of 14 cases with a myeloid neoplasm using cytogenetic, single nucleotide polymorphism array, and next-generation sequencing. We identified n...
Source: Annals of Hematology - December 2, 2021 Category: Hematology Source Type: research

Successful diagnosis of veno-occlusive disease caused by inotuzumab ozogamicin through minimal-invasive angiography: a case report
(Source: Annals of Hematology)
Source: Annals of Hematology - December 2, 2021 Category: Hematology Source Type: research

First report of successful treatment for hemoglobin Bristol-Alesha by hemopoietic stem cell transplantation
AbstractHBB gene mutations lead to many kinds of diseases, of which, except for the two most common diseases of thalassemia and sickle cell anemia, rare kinds of hemolytic anemia, such as hemoglobin Bristol-Alesha, are rarely reported, no ideal treatment in clinic. A child suffered from chronic recurrent hemolytic attacks and the related genes of hereditary hemolytic anemia were detected on her. Hematopoietic stem cell transplantation was conducted in the treatment of the patient. The patient was diagnosed as hemoglobin Bristol-Alesha and achieved complete recovery after hematopoietic stem cell transplantation. For Bristol...
Source: Annals of Hematology - December 1, 2021 Category: Hematology Source Type: research

The anemia-independent impact of myelodysplastic syndromes on health-related quality of life
In this study, we aimed to investigate the anemia-independent impact of MDS on HRQoL. We evaluated participants ( ≥ 50 years) from the large population-based Lifelines cohort (N = 44,694, mean age 59.0 ± 7.4 years, 43.6% male) and the European MDS Registry (EUMDS) (N = 1538, mean age 73.4 ± 9.0 years, 63.0% male), which comprises a cohort of lower-risk MDS patients. To enable comparison concerning HRQoL, SF-36 scores measured in Lifelines were converted to EQ-5D-3L index (range 0–1) and dimension scores. Lower-risk MDS pati...
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation —a single-center analysis
AbstractSecondary immunodeficiencies are frequently observed after allo-HSCT. The efficacy of subcutaneous IgG preparations in this population is unknown. A retrospective single-institution study involved 126 adult patients transplanted in 2012 –2019 for hematological malignancies. Patients were tested every 2–3 weeks for plasma IgG concentration during the 1st year after transplantation and supplemented with facilitated subcutaneous immunoglobulin when they either had IgG concentration 
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

EBV+ posttransplant lymphoproliferative disease of the retina presenting as cytomegalovirus retinitis
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Clonal IgH gene rearrangements identify Richter ’s transformation to diffuse large B cell lymphoma
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Successful myeloablative unrelated bone marrow transplantation for relapsed intravascular large B cell lymphoma after autologous peripheral blood stem cell transplantation
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Plasma cell myeloma with pure lymphocyte-like morphology
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Circulating blastoid cells: acute leukemia, prolymphocytic leukemia, or something else?
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Temozolomide showed rapid activity in a patient with refractory CNS monomorphic epitheliotropic T cell lymphoma
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Stem cell transplantation for hemoglobinopathy Vila Real
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Cutaneous marginal zone lymphoma following anthrax vaccination
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Caplacizumab: frequent local skin reactions
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Questioning the association between ABO type and outcomes in patients with COVID-19
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Coexistence of MYC/BCL2 double-hit of t(8;14)(q24;q32) and t(14;18)(q32;q21) and that of t(8;22)(q24;q11) and t(14;18) in advanced-stage high-grade B cell lymphoma
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Correction to: Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Correction to: Circulating miRNAs and tissue iron overload in transfusion-dependent β-thalassemia major: novel predictors and follow-up guide
(Source: Annals of Hematology)
Source: Annals of Hematology - November 30, 2021 Category: Hematology Source Type: research

Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib
(Source: Annals of Hematology)
Source: Annals of Hematology - November 15, 2021 Category: Hematology Source Type: research

Successful myeloablative unrelated bone marrow transplantation for relapsed intravascular large B cell lymphoma after autologous peripheral blood stem cell transplantation
(Source: Annals of Hematology)
Source: Annals of Hematology - November 15, 2021 Category: Hematology Source Type: research

Circulating blastoid cells: acute leukemia, prolymphocytic leukemia, or something else?
(Source: Annals of Hematology)
Source: Annals of Hematology - November 15, 2021 Category: Hematology Source Type: research

Temozolomide showed rapid activity in a patient with refractory CNS monomorphic epitheliotropic T cell lymphoma
(Source: Annals of Hematology)
Source: Annals of Hematology - November 15, 2021 Category: Hematology Source Type: research

Caplacizumab: frequent local skin reactions
(Source: Annals of Hematology)
Source: Annals of Hematology - November 15, 2021 Category: Hematology Source Type: research

Coexistence of MYC/BCL2 double-hit of t(8;14)(q24;q32) and t(14;18)(q32;q21) and that of t(8;22)(q24;q11) and t(14;18) in advanced-stage high-grade B cell lymphoma
(Source: Annals of Hematology)
Source: Annals of Hematology - November 15, 2021 Category: Hematology Source Type: research

Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre
AbstractGraft-versus-host disease (GVHD) is an important complication after allogeneic haematopoietic stem cell transplantation (HSCT). Corticosteroids are the standard first-line treatment. Steroid-resistant/-dependent (SR/D) acute and chronic GVHD (aGVHD, cGVHD) lead to significant morbidity/mortality. The JAK2 inhibitor ruxolitinib has recently been shown in clinical trials to be effective in SR/D aGVHD and cGVHD. We retrospectively analysed the efficacy and safety of ruxolitinib in a cohort of SR/D aGVHD and cGVHD patients treated in a non-trial setting. In the aGVHD cohort, there were 14 men and 12 women, median age a...
Source: Annals of Hematology - November 12, 2021 Category: Hematology Source Type: research

Spectrum of B-cell neoplasms associated with immunoglobulin G4-related disease
AbstractImmunoglobulin G4-related disease (IgG4-RD) has rarely been associated with lymphoid neoplasms, the spectrum of which remains unclear. B-cell lymphoid neoplasms (LN) associated with IgG4-RD diagnosed in a 4-year period were analysed. There were five men and three women at a median age of 76.5 (52 –90) years; three with synchronous IgG4-RD and LN; three with IgG4-RD preceding LN by 2, 3, and 22 years; and two with LN preceding IgG4-RD by 2.5 and 7 years. All patients presented with disseminated lymphadenopathy. Monoclonal gammopathy of undetermined significance (MGUS)/smouldering multiple myeloma (SM...
Source: Annals of Hematology - November 12, 2021 Category: Hematology Source Type: research

Polatuzumab vedotin –based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
AbstractPolatuzumab vedotin (PoV) has recently shown promising activity when combined with rituximab-bendamustine (BR) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, few studies have described the prognostic factors predicting response. Here, we aimed to evaluate the efficacy and safety profile of PoV-based chemotherapy, including regimens other than BR, as third-line or beyond treatment for patients with R/R DLBCL and to explore prognostic factors. Overall, 40 patients, including 37 with de novo and 3 with transformed DLBCL, were enrolled. The overall response rate was 52.5%, an...
Source: Annals of Hematology - November 11, 2021 Category: Hematology Source Type: research

Epstein-Barr virus –positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma
(Source: Annals of Hematology)
Source: Annals of Hematology - November 10, 2021 Category: Hematology Source Type: research

Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment
(Source: Annals of Hematology)
Source: Annals of Hematology - November 8, 2021 Category: Hematology Source Type: research

Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy
AbstractChromosome 1q gain/amplification (1q  +) has been reported to be associated with inferior outcomes in multiple myeloma (MM) patients. Big therapeutic advances have shifted the treatment landscape by introducing monoclonal antibodies. There is a relative lack of data on outcomes in patients harboring this alteration in the era of mo noclonal antibodies. Baseline characteristics and therapy-related data from newly diagnosed MM patients harboring 1q + detected by fluorescence in situ hybridization (FISH) were collected in a single institution. Among 34 identified subjects, the presence o...
Source: Annals of Hematology - November 8, 2021 Category: Hematology Source Type: research

Clinical effect of CALR allele burden in patients with essential thrombocythemia
(Source: Annals of Hematology)
Source: Annals of Hematology - November 6, 2021 Category: Hematology Source Type: research

Successful treatment of multisystemic Rosai-Dorfman disease with lenalidomide and dexamethasone: a case report
(Source: Annals of Hematology)
Source: Annals of Hematology - November 6, 2021 Category: Hematology Source Type: research

Management of warm autoimmune hemolytic anemia related to band 3-positive colon carcinoma
(Source: Annals of Hematology)
Source: Annals of Hematology - November 5, 2021 Category: Hematology Source Type: research

Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience
AbstractPersistent thrombocytopenia (PT) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with an increased risk of bleeding and poor survival. The exact pathogenesis underlying PT remains unclear, and its management is difficult. Here we conducted a retrospective study to evaluate the efficacy and safety of eltrombopag (EPAG) in 34 patients with PT after allo-HSCT. Seven patients suffered from prolonged isolated thrombocytopenia (PIT), and 27 had secondary failure of platelet recovery (SFPR). For most patients, the initial dose was 25  mg or 50 mg daily, then adjusted to the max...
Source: Annals of Hematology - November 4, 2021 Category: Hematology Source Type: research

Risk factors and outcomes of cytomegalovirus infection in children post cord blood transplantation with focus on impact of graft-versus-host disease and immunosuppressants
In conclusion, CMV infection is common post-CBT in countries with a high rate of CMV seropositivity in the general population and is related to worse outcomes. GVHD severity is associated with the development and recurrence of CMV infection. Thus, efforts need to be made to prevent CMV infection in children post-CBT. (Source: Annals of Hematology)
Source: Annals of Hematology - November 2, 2021 Category: Hematology Source Type: research

Epidemiological shift of glucose-6-phosphate dehydrogenase mutations in northern Italy in the last 15  years
AbstractGlucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive hemolytic anemia caused by mutations in G6PD gene. The distribution and frequency of genetic variants differ depending on ethnicity and geographical areas. Because of new migrations different variants are now present in Europe. This retrospective study aims to identify variants among the G6PD deficient subjects referred since 2004 to IRCCS Ca ’ Granda Foundation Hospital in Milan. The subjects were divided into 3 groups: group 1 (2004–2008), group 2 (2009–2013), and group 3 (2014–2018). During 15 years a signif...
Source: Annals of Hematology - October 13, 2021 Category: Hematology Source Type: research

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
AbstractRecently, there has been increased concern about a risk of secondary malignancies (SM) occurring in myelofibrosis (MF) patients receiving ruxolitinib (RUX). In polycythemia vera (PV), on the other hand, only limited data on the risk of SM under RUX treatment are available. To investigate the association between RUX therapy in PV and SM, we conducted a retrospective, single-center study that included 289 PV patients. RUX was administered to 32.9% (95/289) of patients for a median treatment duration of 48.0  months (range 1.0–101.6). Within a median follow-up of 97 months (1.0–395.0) after PV di...
Source: Annals of Hematology - October 13, 2021 Category: Hematology Source Type: research

Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome
In conclusion, the combination of bortezomib and dexamethasone is effective, with a high response rate and safety profile for patients with newly diagnosed POEMS syndrome. (Source: Annals of Hematology)
Source: Annals of Hematology - October 13, 2021 Category: Hematology Source Type: research

Platelet features allow to differentiate immune thrombocytopenia from inherited thrombocytopenia
AbstractImmune thrombocytopenia (ITP) is an acquired bleeding disorder, for which no specific diagnostic test exists. Inherited thrombocytopenia (IT) can mimic ITP and lead to unappropriated management with significant morbidity. Here, in small cohorts of these two disorders, we explored whether platelet sialylation and platelet activation could allow to discriminate the two conditions. We also aimed to confirm the value of immature platelet counts in this discrimination. Platelet sialylation and the expression level of P-selectin were assessed by multiparameter flow cytometry. Immature platelets were estimated on a Sysmex...
Source: Annals of Hematology - October 13, 2021 Category: Hematology Source Type: research

Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma
AbstractThe Vulnerable Elders Survey-13 (VES-13) is a well-studied simplified frailty screening tool for elderly patients in the oncology setting. We conducted a prospective clinical trial to evaluate the efficacy and safety of dose-adjusted treatment based on the VES-13 in transplant-ineligible patients with newly diagnosed multiple myeloma (MM). In the Fit group (VES-13
Source: Annals of Hematology - October 13, 2021 Category: Hematology Source Type: research

Life-threatening paraneoplastic cardiovascular events in ALK-positive anaplastic large cell lymphoma
(Source: Annals of Hematology)
Source: Annals of Hematology - October 13, 2021 Category: Hematology Source Type: research

JAK2V617F mutation in patients with β-thalassemia disease: prevalence and clinical characteristics
(Source: Annals of Hematology)
Source: Annals of Hematology - October 13, 2021 Category: Hematology Source Type: research

Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin
(Source: Annals of Hematology)
Source: Annals of Hematology - October 13, 2021 Category: Hematology Source Type: research

miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms
(Source: Annals of Hematology)
Source: Annals of Hematology - October 13, 2021 Category: Hematology Source Type: research

Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder
(Source: Annals of Hematology)
Source: Annals of Hematology - October 13, 2021 Category: Hematology Source Type: research